Scott Webster

Professor Scott Webster holds a Personal Chair of Medicines Discovery at the Centre for Cardiovascular Science, University of Edinburgh, where he leads drug discovery research targeting Alzheimer's disease, acute pancreatitis, liver fibrosis, and multiple sclerosis. His work bridges academic and industrial collaboration to advance small molecule therapeutics from laboratory validation to clinical application.

His research group specializes in the full drug discovery pipeline, including target validation, assay development, high-throughput screening, lead optimization, and clinical candidate selection. A major achievement is the development of potent enzyme inhibitors, with the compound UE2343 (Xanamem^TM) progressing through human clinical trials following successful out-licensing. This work addresses critical unmet needs in neurodegenerative, gastrointestinal, and autoimmune disorders through rigorous translational science.

Based at the Queen's Medical Research Institute (Edinburgh BioQuarter), Professor Webster's team includes Translational Projects Manager Andrew McBride and Research Fellow Pierre Rome. His collaborative approach engages multidisciplinary academic and pharmaceutical partners to accelerate therapeutic innovation across complex disease areas.